Education
About Us
Working with TipRanks
Follow Us
Santen Pharmaceutical Co Ltd (JP:4536)
:4536
4536 Stock Chart & Stats
¥1597.00
-¥11.50(-0.71%)
At close: 4:00 PM EST
¥1597.00
-¥11.50(-0.71%)
Day’s Range― - ―
52-Week Range¥1,310.50 - ¥1,790.50
Previous CloseN/A
Volume1.29M
Average Volume (3M)1.30M
Market Cap
¥521.88B
Enterprise Value¥495.39B
Total Cash (Recent Filing)¥61.54B
Total Debt (Recent Filing)¥36.15B
Price to Earnings (P/E)16.7
Beta0.42
Next Earnings
May 12, 2026EPS Estimate
32.71Next Dividend Ex-DateN/A
Dividend Yield2.3%
Share Statistics
EPS (TTM)24.40
Shares Outstanding322,273,960
10 Day Avg. Volume1,416,570
30 Day Avg. Volume1,302,203
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)1.73
Price to Sales (P/S)1.65
P/FCF Ratio9.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)100.06
Revenue Forecast (FY)¥291.19B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and a large equity base provide durable financial flexibility to fund R&D, support launches, and withstand temporary revenue softness. This conservative capital structure reduces refinancing risk and preserves optionality for strategic investments over the next several quarters.
Rebound To Profitable MarginsA return to consistent profitability and double-digit net margins indicates the company has restored earnings power after 2023. Sustainable margins reflect durable cost control and pricing on core ophthalmic products, supporting free cash generation and reinvestment capacity over the medium term.
Specialized Ophthalmology Franchise & Global ReachA focused ophthalmology business and established branded franchises create competitive advantages in product expertise, physician relationships, and lifecycle management. Geographic presence beyond Japan supports diversified revenue streams and allows label expansions and rollouts to extend product life cycles sustainably.
Bears Say
Declining Revenue TrendOngoing revenue declines reduce operating leverage and can erode long-term growth potential if not reversed. Persistent top-line weakness pressures margins, limits reinvestment capacity, and raises execution risk for product launches and lifecycle extensions over the next several quarters.
Weakening Cash Flow MomentumA step-down in operating and free cash flow signals higher working-capital needs or elevated investment spending, reducing excess liquidity. Weaker cash conversion constrains funding for R&D, marketing, or dividends and lowers resilience to prolonged sales softness over 2–6 months.
Exposure To Japan Pricing/regulatory RiskHeavy exposure to Japan's regulated reimbursement framework creates a structural sensitivity to price revisions and policy changes. Because domestic sales drive core revenue, adverse pricing or reimbursement decisions could materially pressure top-line durability and margin sustainability over the medium term.
Santen Pharmaceutical Co News
4536 FAQ
What was Santen Pharmaceutical Co Ltd’s price range in the past 12 months?
Santen Pharmaceutical Co Ltd lowest stock price was ¥1310.50 and its highest was ¥1790.50 in the past 12 months.
What is Santen Pharmaceutical Co Ltd’s market cap?
Santen Pharmaceutical Co Ltd’s market cap is ¥521.88B.
When is Santen Pharmaceutical Co Ltd’s upcoming earnings report date?
Santen Pharmaceutical Co Ltd’s upcoming earnings report date is May 12, 2026 which is in 66 days.
How were Santen Pharmaceutical Co Ltd’s earnings last quarter?
Santen Pharmaceutical Co Ltd released its earnings results on Feb 05, 2026. The company reported ¥24.4 earnings per share for the quarter, missing the consensus estimate of ¥29.293 by -¥4.893.
Is Santen Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Santen Pharmaceutical Co Ltd’s price is currently Overvalued.
Does Santen Pharmaceutical Co Ltd pay dividends?
Santen Pharmaceutical Co Ltd pays a Semiannually dividend of ¥19 which represents an annual dividend yield of 2.3%. See more information on Santen Pharmaceutical Co Ltd dividends here
What is Santen Pharmaceutical Co Ltd’s EPS estimate?
Santen Pharmaceutical Co Ltd’s EPS estimate is 32.71.
How many shares outstanding does Santen Pharmaceutical Co Ltd have?
Santen Pharmaceutical Co Ltd has 322,273,960 shares outstanding.
What happened to Santen Pharmaceutical Co Ltd’s price movement after its last earnings report?
Santen Pharmaceutical Co Ltd reported an EPS of ¥24.4 in its last earnings report, missing expectations of ¥29.293. Following the earnings report the stock price went up 0.881%.
Which hedge fund is a major shareholder of Santen Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in JP:4536
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Santen Pharmaceutical Co Ltd
Santen Pharmaceutical Co., Ltd. (Ticker: 4536) is a global pharmaceutical company headquartered in Japan, specializing in the research, development, manufacturing, and marketing of products primarily for ophthalmology. Established in 1890, Santen focuses on innovative treatments for various eye diseases and conditions, including glaucoma, retinal disorders, and dry eye disease. The company operates in multiple sectors, including prescription pharmaceuticals, over-the-counter (OTC) products, and medical devices, aiming to improve the quality of life for patients worldwide.
Technical Analysis
Astellas Pharma
―
Menicon Co
―
Nipro
―
Tsubota Laboratory Incorporated
―
Japan Eyewear Holdings Co.,Ltd.
―
Options Prices
Currently, No data available
---